Accelerating Cancer Drug Development
Accelerating Cancer Drug Development -From target to patients, BioNow will be hosting this event at Alderley Park on the 27th of February 2018.
Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst showcasing key activities, infrastructure and the joined up translational environment which exists in the North.
Dr Richard Knight will be presenting “Preclinical Safety Evaluation: Lost in Translation?”
Find out more here: Accelerating Cancer Drug Development – From target to patients
Share This Story, Choose Your Platform!
Dr Richard Knight PhD, ERT. A co-founder of ApconiX, Richard is an expert toxicologist with more than 20 years of drug development experience gained in AstraZeneca, where he was part of the Drug Safety and Oncology Leadership Teams. Richard has worked on projects in multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides. He has an in-depth understanding of drug discovery and drug development and has been directly involved in bringing over 35 new candidate drugs to clinical trials and 6 to marketing approval. He uses his extensive experience to bring an innovative, science-led and pragmatic approach to the design and delivery of nonclinical safety programmes.